Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
This study provides reassuring data on the use of mirtazapine during pregnancy, demonstrating no association between exposure and risk of major malformations or pregnancy loss.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Lithium use during pregnancy was associated with an increased risk of preterm birth and large for gestational age infants.
In women with postpartum depression, zuranolone was associated with concurrent improvements in depression, anxiety symptoms, and insomnia beginning at day 3.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the long-term behavioral follow-up of children exposed to mood stabilizers and antidepressants with Ob.Gyn News on August 16,
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
